A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

ID Number 14-1740

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called LY2835219.  An experimental drug is one that is being tested and is not available to buy on the market.

LY2835219 is an oral pill that is being studied due to antitumor activity in breast cancer.  LY2835219 acts in cancer cells to inhibit tumor growth.  In clinical studies, LY2835219 has shown activity against breast cancer both alone and in combination with fulvestrant.  These results support further study of LY2835219 in combination with fulvestrant for women with hormone receptor positive (HR+) breast cancer.

The main reason for you to take part in this study is to help in answering the following research question:

Whether the combination of LY2835219 plus fulvestrant improves outcomes compared to fulvestrant alone for women with a certain type of advanced breast cancer.

Contact Information
Deborah Lehrer
(212) 824-7309

Recruiting Patients: No